Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7060-7071

  Garidou, Lucile ^b   Heydari, Sara ^a   Gossa, Selamawit ^a   McGavern, Dorian B ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Université de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; IMMUNE RESPONSE; INFECTION CONTROL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS NEUTRALIZATION; WILD TYPE;

ANIMALS; ARENAVIRIDAE INFECTIONS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAMMALIA;

EID: 84864140327     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00164-12     Document Type: Article

References (76)

1. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160:521-540.
2. Ahmed R, et al. 1988. Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus. J. Virol. 62:3301-3308.
3. Barber DL, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682- 687.
4. Bellavance EC, et al. 2011. Development of tumor-infiltrating CD8_ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-beta blockade during the perioperative period of tumor resection. J. Immunol. 186:3309 -3316.
5. Berger DP, Homann D, Oldstone MB. 2000. Defining parameters for successful immunocytotherapy of persistent viral infection. Virology 266: 257-263.
6. Berger R, et al. 2008. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14:3044 -3051.
7. Bergthaler A, et al. 2010. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 107:21641-21646.
8. Blackburn SD, et al. 2009. Coregulation of CD8_ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29 -37.
9. Blackburn SD, Wherry EJ. 2007. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 15:143-146.
10. Boni C, et al. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81:4215- 4225.
11. Borrow P, Oldstone MBA. 1997. Lymphocytic choriomeningitis virus. Lippincott-Raven Publishers, Philadelphia, PA.
12. Brooks DG, et al. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12:1301-1309.
13. Brunet JF, et al. 1987. A new member of the immunoglobulin superfamily- CTLA-4. Nature 328:267-270.
14. Cao W, et al. 1998. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282: 2079-2081.
15. Chen ML, et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:419-424.
16. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. 1989. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J. Immunol. 142:1536 -1541.
17. Day CL, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350 -354.
18. Ejrnaes M, et al. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203:2461-2472.
19. Fahlen L, et al. 2005. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 201:737-746.
20. Fantini MC, et al. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25+ T cells through Foxp3 induction and downregulation of Smad7. J. Immunol. 172:5149 -5153.
21. Fazakerley JK, Southern P, Bloom F, Buchmeier MJ. 1991. High resolution in situ hybridization to determine the cellular distribution of lymphocytic choriomeningitis virusRNAin the tissues of persistently infected mice: relevance to arenavirus disease and mechanisms of viral persistence. J. Gen. Virol. 72(Pt 7):1611-1625.
22. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10:554 -567.
23. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236:219 -242.
24. Golden-Mason L, et al. 2007. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81:9249 -9258.
25. Gorelik L, Flavell RA. 2000. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171-181.
26. Gorelik L, Flavell RA. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2:46 -53.
27. Jamieson BD, Somasundaram T, Ahmed R. 1991. Abrogation of tolerance to a chronic viral infection. J. Immunol. 147:3521-3529.
28. Jin HT, et al. 2010. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. 107:14733-14738.
29. Kaech SM, Hemby S, Kersh E, Ahmed R. 2002. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837- 851.
30. Kaufmann DE, et al. 2007. Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246 -1254.
31. Kehrl JH, et al. 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037-1050.
32. Kim JH, et al. 2010. IN-1233, an ALK-5 inhibitor: prevention of granulation tissue formation after bare metallic stent placement in a rat urethral model. Radiology 255:75- 82.
33. Kim PS, Ahmed R. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22:223-230.
34. Komesli S, Vivien D, Dutartre P. 1998. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur. J. Biochem. 254:505-513.
35. Krutzik PO, Nolan GP. 2003. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55:61-70.
36. Kulkarni AB, et al. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90:770 -774.
37. Lauterbach H, Truong P, McGavern DB. 2007. Clearance of an immunosuppressive virus from the CNS coincides with immune reanimation and diversification. Virol. J. 4:53.
38. Lauterbach H, Zuniga EI, Truong P, Oldstone MB, McGavern DB. 2006. Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection. J. Exp. Med. 203:1963-1975.
39. Li MO, Sanjabi S, Flavell RA. 2006. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25:455- 471.
40. Lucas PJ, Kim SJ, Melby SJ, Gress RE. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J. Exp. Med. 191:1187-1196.
41. Marie JC, Letterio JJ, Gavin M, Rudensky AY. 2005. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4_CD25_regulatory T cells. J. Exp. Med. 201:1061-1067.
42. Marie JC, Liggitt D, Rudensky AY. 2006. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25:441- 454.
43. Massague J, Blain SW, Lo RS. 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
44. Mempel TR, et al. 2006. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25:129- 141.
45. Monney L, et al. 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536 -541.
46. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. 2006. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70: 1234-1243.
47. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758 -761.
48. Oldstone MB, Blount P, Southern PJ, Lampert PW. 1986. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 321:239 -243.
49. Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H. 1998. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28:390-400.
50. Petrovas C, et al. 2006. PD-1 is a regulator of virus-specific CD8_ T cell survival in HIV infection. J. Exp. Med. 203:2281-2292.
51. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559 -561.
52. Richter K, Agnellini P, Oxenius A. 2010. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int. Immunol. 22:13-23.
53. Rubtsov YP, Rudensky AY. 2007. TGFbeta signalling in control of T-cellmediated self-reactivity. Nat. Rev. Immunol. 7:443- 453.
54. Sanjabi S, Flavell RA. 2010. Overcoming the hurdles in using mouse genetic models that block TGF-beta signaling. J. Immunol. Methods 353: 111-114.
55. Sevilla N, et al. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192:1249 -1260.
56. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:239 -245.
57. Shull MM, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693- 699.
58. Sullivan BM, et al. 2011. Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc. Natl. Acad. Sci. U. S. A. 108:2969 -2974.
59. Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. 2009. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8_ T cell deletion and viral persistence in vivo. Immunity 31:145-157.
60. Tivol EA, et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547.
61. Traub E. 1938. Factors influencing the persistence of choriomeningitis virus in the blood of mice after clinical recovery. J. Exp. Med. 68:229 -250.
62. Trautmann L, et al. 2006. Upregulation of PD-1 expression on HIVspecific CD8_ T cells leads to reversible immune dysfunction. Nat. Med. 12:1198 -1202.
63. Triebel F, et al. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171:1393-1405.
64. Urbani S, et al. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80: 11398-11403.
65. Velu V, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206 -210.
66. Volkert M. 1963. Studies on immunological tolerance to Lcm virus. 2. Treatment of virus carrier mice by adoptive immunization. Acta Pathol. Microbiol. Scand. 57:465- 487.
67. Volkert M. 1962. Studies on immunological tolerance to LCM virus. A preliminary report on adoptive immunization of virus carrier mice. Acta Pathol. Microbiol. Scand. 56:305-310.
68. Waterhouse P, et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988.
69. Wherry EJ. 2011. T cell exhaustion. Nat. Immunol. 12:492- 499.
70. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911- 4927.
71. Wherry EJ, et al. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670-684.
72. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. 1994. Mechanism of activation of the TGF-beta receptor. Nature 370:341-347.
73. Yata Y, Gotwals P, Koteliansky V, Rockey DC. 2002. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35:1022-1030.
74. Yoon HJ, et al. 2011. Role of IN-1233 in the prevention of neointimal hyperplasia after stent placement in a rat artery model. J. Vasc. Interv. Radiol. 22:1321-1328.
75. Yu S, Fang Y, Sharp GC, Braley-Mullen H. 2010. Transgenic expression of TGF-beta on thyrocytes inhibits development of spontaneous autoimmune thyroiditis and increases regulatory T cells in thyroids of NOD.H-2h4 mice. J. Immunol. 184:5352-5359.
76. Zajac AJ, et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.